List of Excipients in Branded Drug FINGOLIMOD

Generic Drugs Containing FINGOLIMOD

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	fingolimod	0378-4525	AMMONIA
Mylan Pharmaceuticals Inc	fingolimod	0378-4525	DIBASIC CALCIUM PHOSPHATE DIHYDRATE
Mylan Pharmaceuticals Inc	fingolimod	0378-4525	FERRIC OXIDE RED
Mylan Pharmaceuticals Inc	fingolimod	0378-4525	FERRIC OXIDE YELLOW
Mylan Pharmaceuticals Inc	fingolimod	0378-4525	FERROSOFERRIC OXIDE
Mylan Pharmaceuticals Inc	fingolimod	0378-4525	GELATIN
Mylan Pharmaceuticals Inc	fingolimod	0378-4525	GLYCINE

What are the Most Frequently-Used Excipients in FINGOLIMOD?

# Of NDCs	Excipient
3	ALCOHOL
8	AMMONIA
2	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
1	BETADEX
3	BUTYL ALCOHOL
2	CARRAGEENAN
6	CELLULOSE, MICROCRYSTALLINE

Fingolimod Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Fingolimod is a mature, low-dose oral sphingosine-1-phosphate receptor modulator with substantial generic competition and declining originator sales. The strongest excipient opportunities are differentiated oral products that improve swallowability, pediatric administration, dose flexibility, stability, or global manufacturability without creating unnecessary bioequivalence risk. Conventional capsule and tablet products face limited formulation barriers because the active ingredient is used at only 0.5 mg and existing products have relatively simple compositions.

What excipients are used in fingolimod products?

Fingolimod products generally use a small excipient system centered on a diluent, glidant, disintegrant, lubricant, and capsule or tablet coating components.

The U.S. Gilenya capsule contains fingolimod hydrochloride equivalent to 0.5 mg fingolimod. Its inactive ingredients include mannitol, magnesium stearate, colloidal silicon dioxide, gelatin, titanium dioxide, iron oxides, and printing ink components, according to the FDA prescribing information.[1]

Generic compositions vary by manufacturer. Common excipient classes include:

Excipient function	Examples used or commercially relevant	Formulation role
Diluent or filler	Mannitol, lactose, microcrystalline cellulose	Provides capsule or tablet mass
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Promotes rapid product breakup
Glidant	Colloidal silicon dioxide	Improves powder flow
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces tooling and ejection friction
Capsule shell	Gelatin, hypromellose	Encapsulates low-dose drug blend
Colorant	Titanium dioxide, iron oxides	Supports product identification
Film coating	Hypromellose, polyethylene glycol, talc	Protects tablets and controls appearance
Taste-masking system	Polymer coating, ion-exchange resin, lipid barrier	Relevant to liquid or orally disintegrating products

Fingolimod hydrochloride is used in approved oral products. The low dose makes content uniformity, blend homogeneity, and segregation control more important than bulk drug loading. A small amount of active ingredient must be distributed consistently through a substantially larger excipient mass.

Which excipient properties matter most for fingolimod?

Content uniformity and blend segregation

Content uniformity is the principal manufacturing issue for a 0.5 mg dose. Excipient particle-size distribution, density, morphology, and electrostatic behavior can materially affect blend uniformity.

Preferred excipient systems should:

• Match the density and particle-size range of fingolimod hydrochloride.
• Minimize demixing during transfer, compression, or capsule filling.
• Support robust sampling and process validation.
• Avoid excessive lubricant levels that could slow dissolution.
• Maintain assay uniformity after storage and transport.

Direct blending is commercially attractive because it reduces processing steps. Wet granulation may improve uniformity but adds moisture, drying, and scale-up complexity. Roller compaction can improve flow while avoiding water exposure, but its impact on dissolution and compactibility requires product-specific development.

Dissolution and bioequivalence

Fingolimod is administered at a very low dose and has high oral bioavailability. The excipient system generally should support rapid release rather than prolonged or delayed release unless a new clinical and regulatory strategy justifies the development cost.

Risk factors include:

• Excessive magnesium stearate hydrophobicity.
• Over-compression of tablets.
• Excessive polymer coating.
• Strong drug-excipient binding.
• Slow wetting in low-volume pediatric formulations.
• pH-dependent precipitation in liquid products.

For immediate-release generics, simple excipient systems have a strategic advantage because they reduce dissolution variability and make abbreviated approval more predictable.

Moisture and chemical stability

Fingolimod hydrochloride products require control of moisture exposure during granulation, filling, packaging, and storage. Hygroscopic excipients may increase water activity and accelerate degradation or physical changes in the blend.

Commercially useful approaches include:

• Low-moisture direct-compression grades.
• High-barrier blister packaging.
• Desiccant-supported bottles.
• Moisture-resistant capsule shells.
• Stability-indicating analytical methods for impurities and degradation products.

Packaging can be as important as excipient selection. Unit-dose aluminum-aluminum blisters may support premium positioning in markets with difficult storage conditions, while high-density polyethylene bottles generally provide lower cost.

What formulation opportunities exist for fingolimod?

Pediatric oral liquid

A pediatric liquid is the most commercially credible differentiated excipient opportunity. Fingolimod is approved for relapsing forms of multiple sclerosis in pediatric patients aged 10 years and older in the United States, but a capsule or tablet can create administration barriers for patients who cannot swallow solid dosage forms.[1]

A liquid formulation would need to address:

• Low-dose accuracy at 0.5 mg or lower dose levels.
• Uniform suspension or solution concentration.
• Chemical stability over the in-use period.
• Taste masking.
• Compatibility with oral syringes and dosing cups.
• Preservative safety.
• Microbial control.
• Low adsorption to containers and dosing devices.

A true solution could provide the simplest dose measurement if fingolimod hydrochloride remains chemically and physically stable at the target concentration. A suspension may be easier to develop if solubility, taste, or stability limits a solution. Suspending agents such as microcrystalline cellulose and carboxymethylcellulose, xanthan gum, or poloxamers may be considered, but viscosity must remain compatible with accurate syringe dosing.

The opportunity is strongest where pediatric neurologists and caregivers require dose flexibility, but the market is limited by the relatively small pediatric population and the availability of capsules and tablets.

Orally disintegrating tablet

An orally disintegrating tablet could improve administration for patients with dysphagia and reduce the need for water. The 0.5 mg dose is compatible with low-dose ODT development, but content uniformity becomes more challenging as tablet mass decreases.

Potential excipient systems include:

• Mannitol for mouthfeel and fast dissolution.
• Crospovidone or croscarmellose sodium for disintegration.
• Silicified microcrystalline cellulose for compactibility.
• Co-processed excipients for blend uniformity.
• Flavor and sweetener systems for palatability.
• Taste-masking polymers or coated drug particles.

Taste masking is a major technical barrier. A rapidly disintegrating product can expose the active ingredient to the oral cavity, making bitterness more pronounced than in a swallowed capsule.

Sprinkle capsule or multiparticulate formulation

A sprinkle product could allow capsule contents to be administered with soft food. It would require control of particle size, coating integrity, dose recovery, and food compatibility.

The main risks are:

• Inconsistent recovery of the full dose.
• Drug release changes after mixing with food.
• Chewing or crushing of coated particles.
• Stability after opening the capsule.
• Additional labeling and human-factors requirements.

This approach may be more practical than an ODT if the sponsor can use coated multiparticulates with acceptable taste and immediate release.

Modified-release formulations

Modified release is a weaker commercial opportunity. Fingolimod already has an effective once-daily regimen, so extended release would offer limited adherence benefit. A modified-release formulation could theoretically reduce peak exposure or alter tolerability, but it would require a stronger clinical rationale and could face new safety and pharmacokinetic requirements.

Fixed-dose combinations

Fingolimod fixed-dose combinations have limited near-term potential because multiple sclerosis treatment is individualized, combination disease-modifying therapy is uncommon, and safety monitoring is significant. A combination with symptomatic treatments would face clinical, regulatory, and commercial complexity.

How does the fingolimod excipient opportunity compare with competing products?

Product concept	Patient benefit	Development burden	Generic substitution risk	Commercial assessment
Standard 0.5 mg capsule	Low	Low	Very high	Commodity market
Immediate-release tablet	Moderate	Low to moderate	High	Useful where tablet preference matters
Pediatric oral solution	High for selected patients	Moderate to high	Moderate	Best differentiated opportunity
Oral suspension	Moderate to high	Moderate	Moderate	Attractive if stability and taste are solved
ODT	Moderate	Moderate to high	Moderate	Premium niche opportunity
Sprinkle multiparticulate	High for dysphagia	High	Lower initially	Specialized opportunity
Modified release	Uncertain	High	Lower initially	Weak risk-adjusted opportunity
Fixed-dose combination	Uncertain	Very high	Low initially	Limited strategic rationale

The strongest commercial strategy is usually a two-tier portfolio: a low-cost immediate-release generic for volume and a differentiated pediatric or dysphagia product for margin.

When does fingolimod lose exclusivity and what is the generic outlook?

Fingolimod has lost the commercial protection associated with the original Gilenya product in major markets. The active ingredient is a small molecule, so biosimilar regulation does not apply. Competition occurs through abbreviated generic pathways, including ANDAs in the United States and equivalent national or decentralized procedures in Europe.

U.S. FDA status and Orange Book position

Gilenya received FDA approval in 2010 for relapsing forms of multiple sclerosis.[1] The product is listed in the FDA Orange Book as a prescription oral capsule. FDA-approved generic fingolimod products have entered the U.S. market, creating direct price and formulary pressure.[2]

Key regulatory points include:

• The reference product is Gilenya, fingolimod hydrochloride.
• Approved generic strengths are centered on the 0.5 mg daily regimen.
• Generic products must demonstrate pharmaceutical equivalence and bioequivalence.
• A formulation with materially different excipients may still be approvable, but it must satisfy safety, quality, and bioequivalence requirements.
• Pediatric exclusivity and patent-related timing affected the historical launch schedule, but they do not prevent current generic competition.

The FDA Orange Book remains the controlling source for listed patents, exclusivity codes, and approved dosage forms. Patent status can differ by strength, formulation, and jurisdiction.[2]

Patent and litigation considerations

The original fingolimod compound and Gilenya-related patent estate included compound, formulation, dosing, and method-of-use claims. Later patent disputes focused on whether generic products infringed valid claims and whether listed patents could delay approval or launch.

Protection category	Relevance to excipient strategy	Current commercial effect
Compound patents	Broadest historical protection	Generally expired or no longer sufficient to block routine generic entry
Formulation patents	Can cover specific compositions or release profiles	Relevant to differentiated liquid, ODT, or multiparticulate products
Method-of-use patents	May cover dosing or treatment populations	Can create labeling and launch constraints
Manufacturing patents	May cover crystallization, purification, or process controls	More relevant to API suppliers than finished-dose manufacturers
Pediatric exclusivity	Temporarily extends regulatory protection	Historical timing effect
Settlement agreements	Can establish launch dates or licensing rights	Must be reviewed case by case

Paragraph IV challenges were commercially important during the U.S. generic-entry process. A generic applicant can certify that listed patents are invalid, unenforceable, or not infringed. The reference sponsor may then initiate litigation, potentially triggering a 30-month stay under the Hatch-Waxman framework.[3]

A formulation sponsor should avoid relying on a broad excipient concept alone. A defensible patent position generally requires a narrow, measurable technical feature, such as:

• A defined concentration range.
• A specific excipient ratio.
• A controlled particle-size distribution.
• Improved stability under accelerated conditions.
• A particular taste-masking structure.
• A dissolution profile linked to a clinically relevant benefit.
• A manufacturing process that produces superior content uniformity.

What manufacturing and intellectual-property barriers affect fingolimod?

The main manufacturing barrier is not complex drug delivery. It is reliable low-dose manufacture at commercial scale.

Important process controls include:

1. API particle-size and polymorph control.
2. Geometric dilution or controlled premixing.
3. Blend uniformity testing.
4. Segregation control during hopper discharge.
5. Capsule-fill weight control.
6. Tablet assay and content-uniformity testing.
7. Dissolution monitoring.
8. Moisture and impurity control.
9. Container-closure compatibility.
10. Cleaning validation for a potent low-dose API.

A patentable manufacturing advance may have more value than a routine capsule excipient combination. For example, a process that reduces blend variability, eliminates a solvent, improves stability, or permits continuous manufacturing could support licensing to generic manufacturers.

Which companies are competing in fingolimod?

The competitive field includes Novartis as the originator and multiple generic manufacturers. U.S. and international generic competition has involved companies such as Teva, Viatris, Sun Pharma, Zydus, Torrent, and other regional suppliers, depending on jurisdiction and approval status.

Competition is determined by:

• ANDA approval and launch timing.
• Supply reliability.
• Formulary contracts.
• API sourcing.
• Manufacturing cost.
• Product availability across 0.5 mg presentations.
• Regulatory status in individual markets.
• Ability to offer tablets, capsules, or pediatric formats.

The originator’s commercial exposure has declined as generic entry expanded. Novartis reported Gilenya sales of approximately $1.2 billion in 2023, down from earlier peak levels as patent expiry and generic competition affected demand.[4] The remaining value is concentrated in patients who remain on therapy, markets with slower generic substitution, and supply or reimbursement segments where the originator retains access advantages.

What licensing opportunities exist for fingolimod excipients?

The most credible licensing targets are platform technologies rather than undifferentiated fillers.

High-value licensing targets

• Taste-masking systems for pediatric liquids or ODTs.
• Low-dose content-uniformity platforms.
• Moisture-resistant capsule or tablet systems.
• Ready-to-use suspensions with validated dosing devices.
• Co-processed excipients for direct compression.
• Continuous blending and capsule-filling technology.
• Drug-particle coating systems for sprinkle products.
• High-barrier packaging for hot and humid markets.

Lower-value licensing targets

• Standard mannitol and magnesium stearate blends.
• Conventional gelatin capsules.
• Routine immediate-release tablet compositions.
• Non-specific disintegrant combinations without stability or bioequivalence advantages.

Licensing economics are likely to favor a nonexclusive supply or technology agreement rather than an exclusive global license unless the technology creates a distinct product profile, protects a formulation claim, or reduces a major manufacturing failure mode.

How strong is the fingolimod formulation patent opportunity?

The formulation patent opportunity is moderate for specialized dosage forms and weak for conventional capsules.

A standard generic capsule has limited differentiation because the reference formulation is simple and multiple manufacturers can reproduce the essential performance profile. A pediatric liquid, ODT, or sprinkle formulation may support stronger intellectual property if the sponsor can demonstrate measurable advantages.

Patent strength is highest when claims combine:

• Specific excipient identity.
• Quantified concentration ranges.
• Defined particle-size or coating parameters.
• Stability data.
• Dissolution or dose-delivery performance.
• A clear patient or manufacturing benefit.

Method-of-use claims may provide additional protection for pediatric administration, dysphagia, or a particular dosing population, but they face greater enforceability and labeling challenges than composition claims.

What generic launch scenarios exist for fingolimod?

Low-price commodity launch

Multiple suppliers compete on price using standard capsules or tablets. This is the most likely scenario in mature markets. Margins compress rapidly, and supply continuity becomes a key differentiator.

Limited-source launch

Only a small number of suppliers enter because of API, regulatory, or manufacturing constraints. Prices remain above commodity levels for a period, creating an opening for reliable contract manufacturing.

Differentiated pediatric launch

A sponsor launches an oral liquid or flexible-dose product. The market is smaller, but prescribers and caregivers may accept a premium if administration improves.

Regional formulation launch

A company targets countries where solid oral dosage forms remain difficult for pediatric or dysphagic patients and where generic substitution is less aggressive. Local registration, stability data, and packaging adaptation become important.

Key Takeaways

• Fingolimod is a mature small-molecule product with substantial generic competition and no biosimilar pathway.
• Standard capsule and tablet formulations have weak differentiation and limited formulation patent value.
• Low-dose content uniformity, segregation control, dissolution, and moisture management are the main technical priorities.
• Pediatric oral liquids, suspensions, ODTs, and sprinkle products offer the clearest excipient-led commercial opportunities.
• Taste masking, dose accuracy, in-use stability, and device compatibility are the principal barriers to liquid and ODT development.
• Manufacturing-process patents may be more valuable than routine excipient-composition patents.
• U.S. Orange Book listings, FDA ANDA approvals, Paragraph IV litigation, and settlement terms control market-entry timing.
• A two-tier strategy combining a low-cost generic with a differentiated pediatric product offers the strongest commercial logic.
• Novartis’ Gilenya revenue has declined materially as generic competition expanded, reducing the value of undifferentiated originator-style formulations.

FAQs

Can fingolimod be formulated as an oral solution?

Yes. An oral solution is technically feasible, but the sponsor must establish chemical stability, dose uniformity, palatability, preservative control, container compatibility, and accurate delivery through an oral syringe.

Which excipient is best for a fingolimod pediatric liquid?

No single excipient is universally optimal. The selection depends on whether the product is a solution or suspension, with taste masking, viscosity, microbial control, and in-use stability driving the final system.

Does fingolimod have biosimilar competition?

No. Fingolimod is a small-molecule drug. Competition is through generic approval pathways rather than biosimilar regulation.

Can an ODT fingolimod product receive generic approval?

An ODT with a different dosage form would generally require a regulatory pathway appropriate to its formulation and may require additional studies. It would not automatically qualify as a simple generic substitute for a capsule.

Is a fingolimod excipient patent commercially valuable?

It can be valuable when it protects a differentiated pediatric, dysphagia, taste-masked, stable, or manufacturing-efficient product. A routine capsule blend is unlikely to create durable commercial exclusivity.

References

1. U.S. Food and Drug Administration. (2023). Gilenya (fingolimod) prescribing information. Novartis Pharmaceuticals Corporation.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2017). Approved drug products and therapeutic equivalence: Hatch-Waxman provisions and patent certification framework. https://www.fda.gov/

4. Novartis AG. (2024). Annual report 2023. Basel, Switzerland: Novartis AG.

5. European Medicines Agency. (2011). Gilenya: EPAR - product information. https://www.ema.europa.eu/engl/medicines/human/EPAR/gilenya